NEOPLASMS
Clinical trials for NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NEOPLASMS trials appear
Sign up with your email to follow new studies for NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on rare sarcomas in new trial
Disease control CompletedThis phase 2 trial tests a treatment called Lete-Cel, which uses a patient's own immune cells that have been specially trained to attack cancer cells. It is for people with advanced synovial sarcoma or myxoid/round cell liposarcoma whose tumors have a specific marker (NY-ESO-1) a…
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Matched conditions: NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer patients get continued access to promising targeted therapy
Disease control CompletedThis study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…
Matched conditions: NEOPLASMS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Matched conditions: NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Sound waves may help deliver brain tumor drug
Disease control CompletedThis pilot study tested a device called NaviFUS that uses focused ultrasound to temporarily open the blood-brain barrier, combined with the drug bevacizumab (Avastin), in 6 patients with recurrent glioblastoma (a type of brain cancer). The goal was to see if the combination is sa…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Blood cancer drug safety checked in small Follow-Up study
Disease control CompletedThis study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…
Matched conditions: NEOPLASMS
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill shows promise against advanced cancers in early trial
Disease control CompletedThis study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental cancer drug JNJ-70218902 tested in 82 patients
Disease control CompletedThis early-phase study tested a new drug called JNJ-70218902 in 82 people with advanced solid tumors, including prostate cancer. The drug works by redirecting the body's immune T cells to attack cancer cells. The main goals were to find a safe dose and check for side effects, not…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New oral drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental CAR-T therapy targets tough blood cancers in tiny early trial
Disease control CompletedThis early-phase study tested a new cell therapy called RD13-02 in just 2 people with relapsed or refractory CD7-positive blood cancers (like T-cell leukemia or lymphoma). The treatment uses specially engineered immune cells to attack cancer cells. The main goals were to check sa…
Matched conditions: NEOPLASMS
Phase: EARLY_PHASE1 • Sponsor: MEI HENG • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New cancer drug shows promise in early human trial
Disease control CompletedThis early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effect…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo tested for advanced cancers in asian patients
Disease control CompletedThis early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…
Matched conditions: NEOPLASMS
Phase: EARLY_PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug cocktails tested for advanced cancers: hope or hype?
Disease control CompletedThis early-phase trial tested several combinations of cancer drugs, including niraparib, TSR-042, bevacizumab, and various chemotherapies, in 60 patients with advanced or metastatic cancer. The main goal was to find safe doses for future studies. The trial has been completed, but…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug duo shows promise in shrinking tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs (BI 836880 and ezabenlimab) in 252 adults with advanced non-squamous lung cancer and other solid tumors. The first part found the safest dose; the second part checked if the combo could shrink tumors. Participants received…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug called vibostolimab, either alone or combined with other cancer drugs, in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the dr…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo tested for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called MK-4464, given alone or with another drug (pembrolizumab), in 64 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the safety of the drug and how the body processes it. Thi…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 24 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the bo…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug shows early promise in small safety trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New Sugar-Based tracer could spot brain tumors on SPECT scans
Diagnosis CompletedThis study tested a radioactive sugar-like tracer called 99mTc-1-thio-D-glucose to see if it can make brain tumors visible on SPECT scans. Sixteen adults with primary or recurrent brain tumors received one injection, then had scans at several time points. Researchers measured how…
Matched conditions: NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
Could a simple pad replace invasive biopsies for uterine cancer?
Diagnosis CompletedThis study tested a special pad (PadKit™) worn for 4-6 hours to collect cells shed from the uterus. Researchers wanted to see if the pad could gather enough cells to tell the difference between normal tissue, precancerous changes, and cancer. 80 women scheduled for surgery (some …
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
New optical device aims to detect dangerous neutropenia without needles
Diagnosis CompletedThis study tested a device called PointCheck that uses light to check for severe neutropenia (low white blood cells) in cancer patients without needing a blood sample. Researchers enrolled 81 adults with blood or breast cancers who were receiving chemotherapy. The main goal was t…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: Leuko Labs, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
Time-Restricted eating may ease lingering cancer fatigue
Symptom relief CompletedThis study tests whether limiting food intake to a 10-hour window each day for 12 weeks can reduce persistent fatigue in cancer survivors who completed treatment 2 months to 2 years ago. Half the participants follow the eating schedule; the other half receive general healthy life…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Smartphone app aims to boost cancer patient voice during treatment
Symptom relief CompletedThis study tested whether a mobile app helps cancer patients undergoing chemotherapy or radiation therapy report their symptoms more effectively. Over 200 participants used the app to track side effects for 8 weeks. The goal was to see if the app improves how patients recognize a…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: Samsung Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Can virtual physio help kids with leukemia? small study tests hybrid approach
Symptom relief CompletedThis study tested whether a hybrid (in-person and online) physiotherapy program is feasible for children aged 4-17 with acute lymphoblastic leukemia. Ten children and their parents tried the program, which included tailored exercises and games. The goal was to see if families cou…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Talking it out: new study tests emotional writing for chinese cancer patients
Symptom relief CompletedThis study looked at whether a program called expressive helping—where people write or record their feelings—is helpful for Chinese-speaking cancer patients and survivors. About 60 adults with any type of cancer took part. The goal was to see if the program was easy to use and if…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: New York University • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Can money help cure cancer stress? new program targets financial toxicity
Symptom relief CompletedThis study tested a financial navigation program for cancer patients in rural and non-rural North Carolina. The program helped patients find financial assistance to reduce the burden of cancer costs. Researchers measured changes in financial toxicity and quality of life in 258 pa…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Your iPhone could be your next cancer symptom tracker
Knowledge-focused CompletedThis study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…
Matched conditions: NEOPLASMS
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a phone app keep cancer patients on track with their meds?
Knowledge-focused CompletedThis study is testing a new smartphone app designed to help cancer patients remember to take their oral anticancer medications and report any side effects. The app also helps patients communicate with their care team and find support for financial or social needs. Researchers wil…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Cancer clot care under the microscope: new study mines data for better treatment insights
Knowledge-focused CompletedThis study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…
Matched conditions: NEOPLASMS
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
AI learns to spot cancer pain from faces and voices
Knowledge-focused CompletedThis study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…
Matched conditions: NEOPLASMS
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New digital tool helps east asian cancer patients plan care with family
Knowledge-focused CompletedThis study is creating a digital program to help East Asian immigrants with cancer build resilience and start conversations about advance care planning with their families. Researchers will interview religious leaders and test the tool with 84 patients to see if it is easy to use…
Matched conditions: NEOPLASMS
Sponsor: University of Illinois at Chicago • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Antibiotics before kidney drainage: help or hype?
Knowledge-focused CompletedThis study looked at whether giving antibiotics before a kidney drainage procedure (called percutaneous nephrostomy) prevents urinary tract infections in cancer patients whose urinary tract is blocked by a tumor. Researchers reviewed records of 320 cancer patients who had the pro…
Matched conditions: NEOPLASMS
Sponsor: Barretos Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Silent threat: low albumin levels linked to worse outcomes in elderly cancer surgery
Knowledge-focused CompletedThis study looked at 330 older adults (65+) who had cancer surgery to see if low albumin levels before surgery led to more complications. Researchers compared patients with low albumin to those with normal levels, tracking problems like infections, hospital stay length, and ICU n…
Matched conditions: NEOPLASMS
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Could popular diabetes drugs boost cancer survival? new study investigates
Knowledge-focused CompletedThis study analyzed health records of over 200,000 adults with obesity and type 2 diabetes to see if taking GLP-1 drugs (like Ozempic) before a cancer diagnosis is linked to better survival and fewer complications after cancer. The researchers compared GLP-1 users to those on oth…
Matched conditions: NEOPLASMS
Sponsor: Chung Shan Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Could cancer trick the body into attacking its own platelets?
Knowledge-focused CompletedThis study looked at 33 adults who had both immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets — and cancer. Researchers wanted to see if treating the cancer could also improve ITP. They also investigated whether cancer cells might mimic platel…
Matched conditions: NEOPLASMS
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Can a phone app help young cancer survivors get healthy?
Knowledge-focused CompletedThis pilot study tested whether a mobile program could help young adult cancer survivors (ages 18-39) increase physical activity and improve their diet. The program included behavioral lessons, an activity tracker, and simplified diet monitoring using a traffic-light approach. Th…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Cancer patients face higher clot risk – new study aims to understand why
Knowledge-focused CompletedThis study looked at 700 cancer patients to understand how often dangerous blood clots occur and how blood-thinning medications affect them. Researchers tracked patients over two years, analyzing blood samples and clotting events. The goal is to improve prevention and treatment o…
Matched conditions: NEOPLASMS
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC